Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004199 · ClinicalTrials.gov registry record · Phase 3
Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00004199 is a Phase 3 study that has completed, run by Pfizer.
The verdict
NCT00004199, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Prinomastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase III trial to determine the effectiveness of prinomastat plus cisplatin and gemcitabine in treating patients who have metastatic or recurrent non-small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG gemcitabine hydrochloride
- DRUG prinomastat
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004199
The ClinicalTrials.gov registry entry for NCT00004199 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00004199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004199 about?
NCT00004199 is a clinical study titled "Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer". RATIONALE: Prinomastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase III trial to determine the effectiveness of prinomastat plus cisplatin and g...
What is the current status of trial NCT00004199?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-03.
What interventions are being tested in trial NCT00004199?
The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG), prinomastat (DRUG).
Who is sponsoring clinical trial NCT00004199?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.